This page contains brief information about gefitinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Gefitinib is approved to treat:
- Non-small cell lung cancer (NSCLC). It is used in:
- NSCLC that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with other anticancer drugs. For use in these patients, gefitinib is available only as part of a special program called the Iressa Access Program.
- NSCLC with certain epidermal growth factor receptor (EGFR) gene mutations. It is used in patients whose disease has metastasized and who have not been treated with other anticancer drugs.
Gefitinib is also being studied in the treatment of other types of cancer.
More About Gefitinib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Gefitinib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Gefitinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.